Heineken Warns UK Pubs GLP-1 Drugs Could Pressure Beer Sales

Heineken warned UK pub and bar operators that glucagon-like peptide-1 (GLP-1) medications may change drinking habits and pressure beer and cider sales, and urged them to offer smaller pours and lower-alcohol choices.

A presentation shared with UK hospitality customers in October warned that GLP-1 use could mean “fullness and fewer serves,” potentially making multi-pint occasions harder to sustain. It recommended half-pints, low- and no-alcohol drinks, and pairings with small plates.

UK beer sales by value at pubs, bars and restaurants reached £14 billion in the 12 months through Feb. 21, 2026, up 5% from a year earlier. Low- and no-alcohol beer sales totaled £271 million, an increase of 31%. The sales figures do not measure any contribution from GLP-1 use.

In a February 2026 survey, 207 current or former UK GLP-1 users reported drinking alcohol an average of 2.2 days per week after starting medication, down from 3.1 days. They also reported consuming 3.6 UK units a week, compared with 4.3 before starting. The results were self-reported and do not establish that medication caused the changes.

A national probability-based U.S. survey conducted in March and April 2026 included 2,009 respondents. Among respondents who drank when they began treatment, 44.2% said their alcohol use fell in the first three months; 52.6% reported no change, and 3.3% reported an increase. Because responses were retrospective and self-reported, the researchers called for large clinical trials before drawing conclusions about the relationship.

Other alcohol companies have cited limits in the evidence. Diageo’s fiscal 2026 interim presentation described evidence of a lasting effect on total beverage alcohol purchases as limited. Carlsberg has said available data did not yet show GLP-1 drugs were a clear driver of beer-consumption trends.

For the first half of 2026, Heineken reported a 12% increase in low- and no-alcohol volumes and 1.6% growth in total volume. European net revenue was nearly unchanged over the period, as detailed in TokenPost’s earlier coverage of Heineken’s European results.

Heineken described the customer presentation as part of its regular engagement with hospitality businesses. “We see some changes in consumption behaviour among (GLP-1) users and will continue to monitor how these behaviours evolve in 2027,” the company said.